Document is current
Any future updates will be listed below
-
Authors
Deng, Jiayu
Lei, Tianzi
Wang, Xiangfeng
Liu, Changxin
Song, Yanqing
-
Funding
Funding for this research was provided by:
the Jilin Province Department of Finance, China (20200401007MH)
the Science and Technology Department of Jilin Province, China (20200401007MH)
- License Information
-
More Information
Article History
Received: 5 March 2025
Accepted: 4 September 2025
First Online: 3 October 2025
Declarations
:
: This study was conducted in accordance with the principles of the Declaration of Helsinki. It was approved by the Ethics Committee of The First Hospital of Jilin University (19K126-001) and registered on the Chinese Clinical Trial Registry website (, ChiCTR2000031123). Written informed consent was obtained from all participants.
: Not applicable.
: Guhong Injection (Approval Document No.: National Medicine Permit No. H22026638) was produced by Tonghua Guhong Pharmaceutical Co., Ltd (Tonghua, China). The current study was financially supported by Tonghua Guhong Pharmaceutical Co., Ltd. as part of Grant 20200401007MH. The authors declare that Tonghua Guhong Pharmaceutical Co., Ltd. was not involved in the study, and they have no known personal relationships that could have appeared to influence the work reported in this paper.
